NanoViricides (NYSEMKT:NNVC) perks up 7% premarket on light volume in reaction to its announcement that it has selected a drug candidate, dubbed NV-CoV-1-R, for the treatment of COVID-19.
The company says NV-CoV-1-R consists of a nanoviricide, NV-CoV-1 with Gilead Sciences’ (NASDAQ:GILD) remdesivir encapsulated inside its core, adding that NV-CoV-1 is designed to attack the virus particles themselves and “possibly” would also attack infected cells that express a coronavirus antigen called S-protein. Normal cells, which would not display the S-protein, would be unaffected. The encapsulation of remdesivir, it claims, may protect it from rapid metabolism, increasing its stability and effectiveness.
Clinical trials are planned.
https://seekingalpha.com/news/3614465-nanoviricides-picks-covidminus-19-drug-candidate-shares-up-7
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.